文献速递糖尿病

针对眼损伤的尿液蛋白质组可预测2型糖尿病患者的肾损伤:一项病例对照及5.3年前瞻性队列研究

Urine Proteome Specific for Eye Damage Can Predict Kidney Damage in Patients With Type 2 Diabetes: A Case-Control and a 5.3-Year Prospective Cohort Study.
PubMed 文献 · Diabetes Care · 2016-11-30

在2型糖尿病中,微量白蛋白尿对肾损伤的预测价值有限。本研究通过尿液蛋白质组学发现,对增殖性糖尿病视网膜病变特异的尿结合珠蛋白可预测慢性肾功能不全,且与微量白蛋白尿互补。

要点

  • 尿结合珠蛋白≥20 ng/min者慢性肾功能不全发生率高于无此表现者(HR 3.27,95%CI 1.41-7.58,P=0.006)。
  • 无结合珠蛋白尿且无微量白蛋白尿者慢性肾功能不全发生率为3.2%,有微量白蛋白尿者为9.5%,有结合珠蛋白尿者为13.3%。
  • 同时有微量白蛋白尿和结合珠蛋白尿者慢性肾功能不全发生率最高,为22.4%(P<0.001)。

核心结论

  • 对增殖性糖尿病视网膜病变特异的尿结合珠蛋白是预测2型糖尿病患者肾损伤的新型生物标志物,且是尿白蛋白的补充。

研究设计与样本

  • 采用鸟枪法尿液蛋白质组学分析,比较有微量白蛋白尿和增殖性糖尿病视网膜病变的病例组与有微量白蛋白尿且2型糖尿病病程>10年但无任何程度视网膜病变的对照组。
  • 队列研究纳入210例估算肾小球滤过率≥80 mL/min/1.73 m2的2型糖尿病患者,中位随访5.3年,用对增殖性糖尿病视网膜病变特异的尿液蛋白预测慢性肾功能不全(估算肾小球滤过率<60 mL/min/1.73 m2)。

主要发现

  • 病例组与对照组比值差异最大的前两位尿液蛋白为结合珠蛋白(8.7倍;P<0.0001)和α-2-巨球蛋白(5.7倍;P<0.0001)。
  • 基线尿结合珠蛋白≥20 ng/min(结合珠蛋白尿)者慢性肾功能不全发生率高于无结合珠蛋白尿者,风险比(95%CI)为3.27(1.41-7.58),P=0.006。
  • 无结合珠蛋白尿且无微量白蛋白尿者慢性肾功能不全总体发生率为3.2%,有微量白蛋白尿者为9.5%,有结合珠蛋白尿者为13.3%。
  • 同时有微量白蛋白尿和结合珠蛋白尿者慢性肾功能不全发生率最高,为22.4%(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The predictive value of microalbuminuria (MAU) for kidney damage is limited in type 2 diabetes (T2D). We studied whether a urine proteome specific for sight-threatening proliferative diabetic retinopathy (PDR) is an indicator to predict chronic renal insufficiency (CRI) in patients with T2D. RESEARCH DESIGN AND METHODS: A shotgun urine proteomic analysis was performed in patients with MAU and PDR (case subjects) and in patients with MAU and a duration of T2D for >10 years but without any degree of retinopathy (control subjects). In the cohort study, 210 patients with T2D with an estimated glomerular filtration rate (eGFR) ≥80 mL/min/1.73 m2 were followed for a median of 5.3 years. Urine proteins specific for PDR were used for predicting CRI (eGFR <60 mL/min/1.73 m2). RESULTS: The top two urine proteins with the highest difference in ratio of case subjects to control subjects were haptoglobin (8.7 times; P < 0.0001) and α-2-macroglobulin (5.7 times; P < 0.0001). In the cohort study, patients with baseline urinary haptoglobin ≥20 ng/min (haptoglobinuria) had a higher incidence of CRI than those without (hazard ratio [95% CI] 3.27 [1.41-7.58]; P = 0.006). The overall CRI rate was 3.2% for patients without haptoglobinuria or MAU, 9.5% for those with MAU, and 13.3% for those with haptoglobinuria. The highest rate for CRI (22.4%) was in patients with both MAU and haptoglobinuria (P < 0.001). CONCLUSIONS: Urine haptoglobin, which is specific for PDR, is a novel biomarker and complement to urine albumin for predicting kidney damage in patients with T2D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Yang JK, Wang YY, Liu C, et al. Urine Proteome Specific for Eye Damage Can Predict Kidney Damage in Patients With Type 2 Diabetes: A Case-Control and a 5.3-Year Prospective Cohort Study. Diabetes Care. 2016. PMID: 27903615. doi:10.2337/dc16-1529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。